Real-world effectiveness of SGLT2 inhibitors in patients with HF and ESKD: a multicenter cohort study.

ABSTRACT:

Background

Patients with heart failure (HF) and end-stage kidney disease (ESKD) face a high burden of mortality and hospitalization, yet effective therapeutic options remain limited. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits across various chronic kidney disease (CKD) stages, their effects in patients with HF and ESKD remain uncertain due to their exclusion from major clinical trials.

Objectives

This study aimed to evaluate the effectiveness of SGLT2i in reducing one-year clinical outcomes, including all-cause hospitalization, all-cause mortality, and acute pulmonary edema in patients with HF and ESKD.

Methods

A retrospective cohort study was conducted using the TriNetX network. Patients with HF and ES

SUBMITTER: Wu JY 

PROVIDER: S-EPMC12856922 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature